CLAIMS

1. Use of a *N. meningitidis* conjugate vaccine in the manufacture of a medicament for the prevention or treatment of *N. meningitidis* disease in a human patient, wherein:

- the human patient has been immunised at a first age of between 0 and 11 months with a bacterial saccharide conjugate vaccine comprising at least two or three bacterial saccharide(s) conjugated to a carrier protein to form at least two or three bacterial saccharide conjugate(s), wherein the at least two or three bacterial saccharide conjugate(s) comprise a *N. meningitidis* serogroup C (MenC) capsular saccharide;
- the *Neisseria meningitidis* conjugate vaccine to be used in the manufacture of the medicament comprises *N. meningitidis* serogroup A capsular saccharide (MenA), *N. meningitidis* serogroup C capsular saccharide (MenC), *N. meningitidis* serogroup W135 capsular saccharide (MenW135), and *N. meningitidis* serogroup Y capsular saccharide (MenY) conjugated separately to a carrier protein, and wherein the *Neisseria meningitidis* conjugate vaccine is to be co-administered with a DTPa vaccine to the human patient at a second age of between 12 and 24 months.

2. Use according to claim 1 wherein the at least two or three bacterial saccharide(s) of the bacterial saccharide conjugate vaccine that the human patient has been immunised with at a first age of between 0 and 11 months comprise a *Haemophilus influenza* (Hib) saccharide.

3. Use according to claim 1 or 2 wherein the at least two or three bacterial saccharide(s) of the bacterial saccharide conjugate vaccine that the human patient has been immunised with at a first age of between 0 and 11 months comprise a *N. meningitidis* serogroup Y (MenY) capsular saccharide.

4. Use according to any one of claims 1-3 wherein the carrier protein of the bacterial saccharide conjugate vaccine that the human patient has been immunised with at a first age of between 0 and 11 months is tetanus toxoid, diphtheria toxoid or CRM197.

5. Use according to claim 4 wherein the carrier protein of the bacterial saccharide conjugate vaccine that the human patient has been immunised with at a first age of between 0 and 11 months is tetanus toxoid, optionally at a total TT content of 5-40, 10-30, 15-20μg or about 18μg per dose.

6. Use according to any one of claims 1-5 wherein the human patient has been immunised with 2 or 3 doses of the bacterial saccharide conjugate at a first age of between 0 and 11 months, optionally at 2, 4 and 6 months of age.

7. Use according to any one of claims 1-6 wherein the human patient is to be co-administered at a second age of between 12 and 24 months the *Neisseria meningitidis* conjugate vaccine and the vaccine comprising diphtheria toxin and tetanus toxin leading to an at least 10% increase in immunogenity against at least one of MenA, MenC, MenW135 or MenY compared to if the *Neisseria meningitidis* conjugate vaccine is administered alone, optionally measured by SBA assay.

8. Use according to any one of claims 1-7 wherein the human patient has been immunised at a first age of between 0 and 11 months with the bacterial saccharide conjugate vaccine administered at the same time as a vaccine comprising DTP.

9. Use according to any one of claims 1-8 wherein the human patient is to be immunised at a second age of between 12 and 24 months with a bacterial saccharide conjugate vaccine comprising a carrier protein selected from the group consisting of tetanus toxoid, diphtheria toxoid or CRM197.

10. Use according to claim 9 wherein the human patient is to be immunised at a second age of between 12 and 24 months with a bacterial saccharide conjugate vaccine comprising tetanus toxoid as the carrier protein.

11. Use according to any one of claims 1-10 wherein the carrier protein of the immunisation at a first age of between 0 and 11 months and the bacterial saccharide

conjugate vaccine to be administered at a second age of between 12 and 24 months are the same.

12. Use according to any one of claims 1-11 wherein the human patient is to be immunised with the bacterial saccharide conjugate vaccine at between 12 and 18 months of age.

13. Use according to claim 12 wherein the human patient is to be immunised with the bacterial saccharide conjugate vaccine at between 15-18 months of age.